OIS Index Outperforms

OIS Index Outperforms

The OIS Index of ophthalmic stocks gained 5.4% in November, following a similar 5.2% gain in October. The index outperformed medical device stocks (+4.3%) and the broader US stock market (+3.6%) but lagged the biotech sector (+11.4%).

The largest positive contributor was Adverum Biotechnologies (+50.1%), which continued its steady rebound from a September decline related to the company’s Phase 1 gene therapy study in wet AMD. The largest percentage gainer was Eyenovia (+53.8%), which moved higher following the company’s Q3 financial report and business update.

Other ophthalmic stocks that participated in the November biotech rally included Aldeyra Therapeutics (+42.8%), KalVista Pharmaceuticals (+36.6%), MeiraGTx (+33.4%), and Alimera Sciences (+33.2%). Two of the large diversified ophthalmic device companies, Bausch Health (+13.7%) and Carl Zeiss Meditec (+12.9%), also contributed significantly to index performance.

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

MicrosoftTeams-image (68)

OIS Retina@ASRS Brings Retina Leaders Together (Again) for Live Meeting in San Antonio

Pod 298 - Gary Wortz - Thumbnail (2)

Revolutionizing Cataract Surgery from Innovation to Commercialization

MicrosoftTeams-image (55)

Despite Mixed Trial Results and Stock Plunge, Apellis Keeps Commitment to Lead Candidate Pegcetacoplan

Pod 297 - Damon Burrows - Thumbnail

From Big Pharma Lawyer to Eye Care Disruptor: IACTA Pharmaceuticals Founder & CEO Damon Burrows

OIS Summit FDA Approved (2)

Judy Gordon’s Legacy: Helping Firms Navigate a Path to FDA Approval of Transformative Technology

Bausch + Lomb

OSD Pipeline Update: Etiology-Specific Treatments for MGD, Demodex Getting Closer

About The Author

Michael Lachman

Michael Lachman is President of EyeQ Research, which provides market research, analytics, and strategic advisory to ophthalmic companies and investors. Previously, he was a healthcare investment research analyst with Hambrecht & Quist, ThinkEquity Partners, and SAC Capital, and worked in business development, marketing, and R&D for Johnson & Johnson and Baxter.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

PODCASTS